SecBot SecBot

RZLT

Rezolute, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001509261 Biotech & Drug Discovery
$4.03 +0.21 (+5.37%)
Oct 27 4:00 PM ET · prev $3.82
Market cap
$372.9M
Small cap
Consensus
Buy
88% Buy or better · 17 analysts
Median target
$10.00
+148% · range $6.00–15.00
Next earnings
Nov 4
in 8 days · EPS est. −$0.18
1 year
−57.4%
from $9.45 · Oct 27
30 days
−3.7%
from $4.18
52-week range
$1.40–10.94
−63% from high · low Dec 11
Avg volume 20D
1.64M
Oct 5 spike 4.20M
Short interest
🔒 Subscribers only
Insider net
+$28.5K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 4, 2026
Strongest NEUTRAL Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $28.5K at an average $2.85. No open-market sales. Price is 41% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 25 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    15 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.146 → −$0.185 over 90 days. 0 up, 4 down in 30 days.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JACOBS LEVY EQUITY MANAGEMENT, INCDOUBLED2,561,654$13.3M
JENNISON ASSOCIATES LLCTRIM2,459,308$12.8M
MORGAN STANLEYTRIM1,618,783$8.4M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM1,380,746$7.2M
GOLDMAN SACHS GROUP INCDOUBLED1,316,782$6.8M
Nuveen, LLCDOUBLED1,295,209$6.7M
DIMENSIONAL FUND ADVISORS LPADD890,733$4.6M
BANK OF AMERICA CORP /DE/NEAR_EXIT730,332$3.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 88% rate it Buy or better
Strong Buy6Buy9Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +148%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026Lake Street
MAINTAIN
MAINTAINBuy
Oct 6, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Oct 6, 2026Cantor Fitzgerald
UPGRADE
UPGRADEOverweight
Sep 30, 2026Lake Street
INITIATE
INITIATEBuy
Sep 29, 2026Craig-Hallum
UPGRADE
UPGRADEBuy
Sep 25, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$28.5K
bought · 1 insider
$0
sold · 0 insiders
+41.2%
vs their $2.85 cost
DateInsiderTypeValue
Oct 21, 2026
Evans Daron
CFO
GIFT16,000 sh
Oct 21, 2026
Evans Daron
CFO
GIFT4,000 sh
Sep 2, 2026
Karnawat Sunil Ratilal
Chief Commercial Officer
TAX W/H$10.2K
Jul 2, 2026
Evans Daron
CFO
TAX W/H$15.3K
Jul 2, 2026
Elam Nevan C
CEO
TAX W/H$39.9K
Jul 2, 2026
ROBERTS BRIAN KENNETH
Chief Medical Officer
TAX W/H$15.3K
Mar 30, 2026
Evans Daron
CFO
BUY$28.5K
Mar 2, 2026
ROBERTS BRIAN KENNETH
Chief Medical Officer
TAX W/H$34.2K

Earnings setup

Estimates
Nov 4
reports in 8 days
−$0.18
EPS estimate, this quarter
−27%
estimate change, 90 days
0↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.18-$0.21–-$0.15-26.7%$0.00
Next Q-$0.17-$0.21–-$0.14-30.9%$0.00
Current FY-$0.70-$0.84–-$0.57-11.4%$2.1M
Next FY-$0.47-$0.97–-$0.15-67.3%$54.1M

Washington

Corporate Lobbying

13 lobbying filings and 1 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for seven…
DEF 14A — Impact 5/10
Oct 21, 2026 Insider
Evans Daron gifted 16,000 shares
CFO
Oct 21, 2026 Insider
Evans Daron gifted 4,000 shares
CFO
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Oct 14, 2026 SEC
Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with…
8-K — Impact 5/10
Oct 5, 2026 SEC
Rezolute announced that the FDA recommended a pre-BLA meeting as a precursor to submitting a Biologics License…
8-K — Impact 6/10
Sep 2, 2026 Insider
Karnawat Sunil Ratilal surrendered for taxes 2,267 shares
Chief Commercial Officer @ $4.50 ($10.2K)
Jul 21, 2026 Press
Rezolute announced management participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. This is…
Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
RZLT Q1 2027 Earnings Scheduled — 2026-11-04
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Oct 5, 2026
Press release
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these…
Sep 24, 2026
Earnings
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare…
Sep 24, 2026
Earnings result
RZLT Q4 2026 Earnings: EPS $-0.2 (-32.5% vs est)
Sep 15, 2026
Earnings date
RZLT Q4 2026 Earnings After Market Close — 2026-09-15

SecBot reports

11 filings · 2 press releases · 1 bullish · 4 bearish · 2 mixed · 4 neutral
All RZLT filing & press-release reports (13)